A********e
发帖数: 354 | 1 【 以下文字转载自 Biology 讨论区 】
发信人: albertsmwk (.)(.), 信区: Biology
标 题: 第一批“青年千人计划”生物类@publication列表@
发信站: BBS 未名空间站 (Thu Aug 18 15:04:16 2011, 美东)
花了一个小时，深深的鄙视一下自己的无聊行径！！
125 蔡亮 男 1980年11月 复旦大学 生命
科学 2007年12月毕业于[美国]北卡大学 [美国]加州大学旧金山分校 博士后
Cai L, Mostov K. Polarity is destiny. Cell. 2009 Nov 13;139(4):660-2. PubMed
PMID: 19914162; PubMed Central PMCID: PMC2900917.
Cai L, Makhov AM, Schafer DA, Bear JE. Coronin 1B antagonizes cortactin and
remodels Arp2/3-containing actin branche... 阅读全帖 |
|
p*******g
发帖数: 2976 | 2 【 以下文字转载自 Biology 讨论区 】
发信人: albertsmwk (.)(.), 信区: Biology
标 题: 第一批“青年千人计划”生物类@publication列表@
发信站: BBS 未名空间站 (Thu Aug 18 15:04:16 2011, 美东)
花了一个小时，深深的鄙视一下自己的无聊行径！！
125 蔡亮 男 1980年11月 复旦大学 生命
科学 2007年12月毕业于[美国]北卡大学 [美国]加州大学旧金山分校 博士后
Cai L, Mostov K. Polarity is destiny. Cell. 2009 Nov 13;139(4):660-2. PubMed
PMID: 19914162; PubMed Central PMCID: PMC2900917.
Cai L, Makhov AM, Schafer DA, Bear JE. Coronin 1B antagonizes cortactin and
remodels Arp2/3-containing actin branche... 阅读全帖 |
|
O***n
发帖数: 13127 | 3 【 以下文字转载自 Biology 讨论区 】
发信人: albertsmwk (.)(.), 信区: Biology
标 题: 第一批“青年千人计划”生物类@publication列表@
发信站: BBS 未名空间站 (Thu Aug 18 15:04:16 2011, 美东)
花了一个小时，深深的鄙视一下自己的无聊行径！！
125 蔡亮 男 1980年11月 复旦大学 生命
科学 2007年12月毕业于[美国]北卡大学 [美国]加州大学旧金山分校 博士后
Cai L, Mostov K. Polarity is destiny. Cell. 2009 Nov 13;139(4):660-2. PubMed
PMID: 19914162; PubMed Central PMCID: PMC2900917.
Cai L, Makhov AM, Schafer DA, Bear JE. Coronin 1B antagonizes cortactin and
remodels Arp2/3-containing actin branche... 阅读全帖 |
|
p*****n
发帖数: 981 | 4 ☆─────────────────────────────────────☆
MyResearch (astnt的马甲) 于 (Fri Feb 9 02:01:07 2007) 提到:
From: astnt.myresearchspace.cn
全贴：
http://www.myresearchspace.cn/bbs/thread-1820-1-1.html
新生血管生成(3)－各种因子balance的结果
新生血管生成过程受血管生成正负因子的共同调控。 Hanahan等人提出“血管形成的开
关平衡假说”(the balance hypothesis for the angiogenic switch)，认为生长因子
的浓度上升或抑制因子的浓度下降使开关处于开放状态导致血管形成。目前已发现的血
管形成正负调节因子有四五十种，下面的图列出了几种。
参考文献：
Hanahan, D. and Folkman, J. Patterns and emerging mechanisms of the
angiogenic switch during tumorigenesis. |
|
b**********t
发帖数: 366 | 5 1.
Journal: Current drug targets
Title: Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for
Cancer Therapy
Author: Niu, etc
Year 2010, Volume 11, Issue 8, Page 1000-1017
Link:
http://www.ncbi.nlm.nih.gov/pubmed/20426765
2.
Journal: Expert opinion on biological therapy
Title: Oligosaccharides as anti-angiogenic agents
Author: Cole, etc
Year 2008, Volume 8, Issue 3, Page 351-362
Link:
http://www.ncbi.nlm.nih.gov/pubmed/18294105
My email: b********[email protected]
Thanks a lot! :) |
|
a********k
发帖数: 2273 | 6 花了一个小时，深深的鄙视一下自己的无聊行径！！
125 蔡亮 男 1980年11月 复旦大学 生命
科学 2007年12月毕业于[美国]北卡大学 [美国]加州大学旧金山分校 博士后
Cai L, Mostov K. Polarity is destiny. Cell. 2009 Nov 13;139(4):660-2. PubMed
PMID: 19914162; PubMed Central PMCID: PMC2900917.
Cai L, Makhov AM, Schafer DA, Bear JE. Coronin 1B antagonizes cortactin and
remodels Arp2/3-containing actin branches in lamellipodia. Cell. 2008 Sep
5;134(5):828-42. PubMed PMID: 18775315; PubMed Central PMCID: PMC2570342.
Cai L, Makhov AM, Bear JE. F-actin... 阅读全帖 |
|
H*Q
发帖数: 725 | 7 email, h********[email protected]
thanks a million
Nat Med. 2011 Nov 7;17(11):1359-70. doi: 10.1038/nm.2537.
Tumor angiogenesis: molecular pathways and therapeutic targets.
Weis SM, Cheresh DA.
Source
Department of Pathology and Moores University of California-San Diego Cancer
Center, University of California-San Diego, La Jolla, California, USA.
Abstract
As angiogenesis is essential for tumor growth and metastasis, controlling
tumor-associated angiogenesis is a promising tactic in limiting cancer
pro... 阅读全帖 |
|
p*******g
发帖数: 2976 | 8 【 以下文字转载自 Biology 讨论区 】
发信人: albertsmwk (.)(.), 信区: Biology
标 题: 第一批“青年千人计划”生物类@publication列表@
发信站: BBS 未名空间站 (Thu Aug 18 15:04:16 2011, 美东)
花了一个小时，深深的鄙视一下自己的无聊行径！！
125 蔡亮 男 1980年11月 复旦大学 生命
科学 2007年12月毕业于[美国]北卡大学 [美国]加州大学旧金山分校 博士后
Cai L, Mostov K. Polarity is destiny. Cell. 2009 Nov 13;139(4):660-2. PubMed
PMID: 19914162; PubMed Central PMCID: PMC2900917.
Cai L, Makhov AM, Schafer DA, Bear JE. Coronin 1B antagonizes cortactin and
remodels Arp2/3-containing actin branche... 阅读全帖 |
|
t******l
发帖数: 32 | 9 可以咨询一下医生，能不能用cyramza. 去年FDA刚批的药，是anti-angiogenic agent.
基本没有毒副作用。
药理就是阻断癌细胞需要的血管。效果还不错，可以看一下。
Bless!
★ 发自iPhone App: ChineseWeb 8.6 |
|
M********s
发帖数: 104 | 10 以前网上淘到的一个,
College of _____
Department of __________
XXX ____ Avenue, 7th Floor
(city), (State) (zip) (推荐人地址)
August 12, 2007
U.S. Citizenship & Immigration Services
Nebraska Service Center
850 “S” Street Lincoln, NE 68508
Re: Dr. ____ ___ (your full name)
Dear Sir/Madam,
I strongly support the National Interest Waiver application for ______ ___,
M.D, Ph.D.. Dr. ___ is an extraordinary young scientist who is making
significant contributions to our understanding of ... 阅读全帖 |
|
p*****4
发帖数: 366 | 11 PEDF in Angiogenic Eye Diseases
Author: Tombran-Tink, J.
Source: Current Molecular Medicine, Volume 10, Number 3, April 2010 , pp.
267-278(12)
不胜感激 |
|
h******y
发帖数: 351 | 12 Characterization of a novel angiogenic model based on stable, fluorescently
labelled endothelial cell lines amenable to scale-up for high content
screening
http://onlinelibrary.wiley.com/doi/10.1042/BC20100146/pdf
BIOLOGY OF THE CELL Volume: 103 Issue: 10 Pages: 467-481 DOI: 10.1042
/BC20100146 Published: OCT 2011
Please send it to z*****[email protected]
Thank you very much. |
|
p*****4
发帖数: 366 | 13 Anti-angiogenic and anti-neuroinflammatory effects of kallistatin through
interactions with the canonical Wnt pathway. |
|
l******g
发帖数: 13 | 14 http://www.ncbi.nlm.nih.gov/pubmed/20718701
Curr Cancer Drug Targets 2010, August 19.
the authors are: D Mottet and V Castronovo.
The title of the article is “Histone Deacetylases: Anti-Angiogenic Targets
in Cancer Therapy” |
|
u*****e
发帖数: 357 | 15 Need dissertation copy: PROQUEST
Reinventing fibrin: Development of angiogenic tissue engineered scaffolding
Please email me at w****[email protected]
Thanks a lot. |
|
f**********g
发帖数: 2252 | 16 来自主题: _pennystock版 - vicl SLOW COW.
Publication Highlights Allovectin-7(R) Phase 2 Safety and Efficacy Results
in Melanoma
6 hours 15 minutes ago - PMZ
GlobeNewswireVical Incorporated (Nasdaq:VICL) today announced a new
publication summarizing results from the company's completed trials of
Allovectin-7(R) including systemic responses and an excellent safety profile
in patients with metastatic melanoma. An article published in the January
issue of Immunotherapy1 noted that the U.S. incidence of melanoma is
increasing rapi... 阅读全帖 |
|
f**********g
发帖数: 2252 | 17 来自主题: _pennystock版 - vicl SLOW COW.
Publication Highlights Allovectin-7(R) Phase 2 Safety and Efficacy Results
in Melanoma
6 hours 15 minutes ago - PMZ
GlobeNewswireVical Incorporated (Nasdaq:VICL) today announced a new
publication summarizing results from the company's completed trials of
Allovectin-7(R) including systemic responses and an excellent safety profile
in patients with metastatic melanoma. An article published in the January
issue of Immunotherapy1 noted that the U.S. incidence of melanoma is
increasing rapi... 阅读全帖 |
|
f**********g
发帖数: 2252 | 18 VICL are strong.
Vical to Present at Bank of America/Merrill Lynch Health Care Conference
4 hours 9 minutes ago - PMZ via Comtex
GlobeNewswireVical Incorporated (Nasdaq:VICL) today announced that Vijay B.
Samant, President and Chief Executive Officer, will provide an overview of
the company's technologies, development programs, and outlook on Wednesday,
May 11, at 3:00 p.m. PDT (6:00 p.m. EDT) at the Bank of America/Merrill
Lynch Health Care Conference (Las Vegas, May 10 -- 12).
A webcast of Mr.... 阅读全帖 |
|
f**********g
发帖数: 2252 | 19 Vical Presentations on TransVax(TM) and DNA Vaccines at ASGCT Conference
3 hours 35 minutes ago - PMZ via Comtex
GlobeNewswireVical Incorporated (Nasdaq:VICL) announced today that the
company will present a summary of Phase 2 data for the company's TransVax(TM
) therapeutic cytomegalovirus (CMV) vaccine, and a review of clinical-stage
DNA vaccine development programs, both at the 14th Annual Meeting of the
American Society of Gene & Cell Therapy, (Seattle -- May 18-21).
Alain P. Rolland, Pharm.D... 阅读全帖 |
|
y*****9
发帖数: 43 | 20 感谢版主邀请，既然进来了，怎么也得贡献一点心得。这个就再这里首发了~~
这两个股票目前都还是低价股，但是都属于同一类股票。都是与血液肿瘤（癌症）相关
的BIO公司。
医药股的特点不是EPS，不是REV，（当然这些仍是成熟BIO的特点）对于研发阶段的BIO
，最重要的是它的实验数据（trial data).每次关键的data公布都会成为股价的催化剂。
SNTA: 最近两日的大涨都源自于本月底前后的data
Preliminary results from the GALAXY trial are expected in the second quarter
of 2012, and additional results from the GALAXY trial together with
preliminary results from the ALK+ lung cancer and breast cancer trials are
expected in the second half of 2012. In addition to the company-sponsored
tr... 阅读全帖 |
|
